Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEN NYSE:IKT NASDAQ:MRNS NASDAQ:TARA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$1.37-1.1%$1.48$1.13▼$2.66$121.81M2.58381,174 shs139,410 shsIKTInhibikase Therapeutics$1.56-2.3%$1.75$1.12▼$4.20$116.55M0.91182,432 shs21,540 shsMRNSMarinus Pharmaceuticals$0.55-0.2%$0.55$0.22▼$1.97$30.32M1.031.94 million shs260 shsTARAProtara Therapeutics$3.12-1.3%$3.16$1.60▼$10.48$120.38M1.52310,038 shs40,016 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen+2.99%-4.83%-3.50%-16.36%-29.95%IKTInhibikase Therapeutics+2.56%-3.61%-8.57%-8.05%+35.59%MRNSMarinus Pharmaceuticals0.00%0.00%0.00%0.00%-63.39%TARAProtara Therapeutics+0.64%+2.93%+4.29%+3.27%+68.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$1.37-1.1%$1.48$1.13▼$2.66$121.81M2.58381,174 shs139,410 shsIKTInhibikase Therapeutics$1.56-2.3%$1.75$1.12▼$4.20$116.55M0.91182,432 shs21,540 shsMRNSMarinus Pharmaceuticals$0.55-0.2%$0.55$0.22▼$1.97$30.32M1.031.94 million shs260 shsTARAProtara Therapeutics$3.12-1.3%$3.16$1.60▼$10.48$120.38M1.52310,038 shs40,016 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen+2.99%-4.83%-3.50%-16.36%-29.95%IKTInhibikase Therapeutics+2.56%-3.61%-8.57%-8.05%+35.59%MRNSMarinus Pharmaceuticals0.00%0.00%0.00%0.00%-63.39%TARAProtara Therapeutics+0.64%+2.93%+4.29%+3.27%+68.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGENCompugen 3.00Buy$4.00193.04% UpsideIKTInhibikase Therapeutics 2.50Moderate Buy$6.50315.60% UpsideMRNSMarinus Pharmaceuticals 2.44Hold$3.92613.29% UpsideTARAProtara Therapeutics 3.17Buy$19.60528.21% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGENCompugen$22.14M5.50N/AN/A$0.62 per share2.20IKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/AMRNSMarinus Pharmaceuticals$30.99M0.98N/AN/A$0.31 per share1.77TARAProtara TherapeuticsN/AN/AN/AN/A$4.77 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGENCompugen-$14.23M-$0.22N/AN/AN/A-87.45%-34.77%-16.82%11/11/2025 (Estimated)IKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/AMRNSMarinus Pharmaceuticals-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%N/ATARAProtara Therapeutics-$44.60M-$1.62N/AN/AN/AN/A-36.87%-33.85%11/11/2025 (Estimated)Latest MRNS, TARA, CGEN, and IKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025TARAProtara Therapeutics-$0.43-$0.35+$0.08-$0.35N/AN/A8/6/2025Q2 2025CGENCompugen-$0.07-$0.08-$0.01-$0.08$3.95 million$1.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGENCompugenN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AMRNSMarinus PharmaceuticalsN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGENCompugenN/A4.744.74IKTInhibikase TherapeuticsN/A0.850.85MRNSMarinus PharmaceuticalsN/A1.661.47TARAProtara TherapeuticsN/A12.8112.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGENCompugen12.22%IKTInhibikase Therapeutics3.81%MRNSMarinus Pharmaceuticals98.80%TARAProtara Therapeutics38.13%Insider OwnershipCompanyInsider OwnershipCGENCompugen9.50%IKTInhibikase Therapeutics7.30%MRNSMarinus Pharmaceuticals5.46%TARAProtara Therapeutics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGENCompugen7089.24 million80.76 millionOptionableIKTInhibikase Therapeutics674.52 million66.18 millionNot OptionableMRNSMarinus Pharmaceuticals11055.22 million52.20 millionOptionableTARAProtara Therapeutics3038.58 million33.76 millionOptionableMRNS, TARA, CGEN, and IKT HeadlinesRecent News About These CompaniesProtara Therapeutics, Inc. (NASDAQ:TARA) Receives $19.60 Consensus PT from AnalystsSeptember 16 at 2:33 AM | americanbankingnews.comIdentifying Undervalued and Overlooked Assets to Address Unmet Patient NeedsSeptember 15 at 10:56 PM | fiercebiotech.comFProtara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of "Buy" by BrokeragesSeptember 15 at 2:08 AM | marketbeat.comDriehaus Capital Management LLC Sells 244,810 Shares of Protara Therapeutics, Inc. $TARASeptember 3, 2025 | marketbeat.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2, 2025 | globenewswire.comVelan Capital Investment Management LP Buys 88,800 Shares of Protara Therapeutics, Inc. $TARAAugust 31, 2025 | marketbeat.comProtara Therapeutics to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comCantor Fitzgerald Brokers Raise Earnings Estimates for TARAAugust 22, 2025 | marketbeat.comProtara Therapeutics, Inc. (NASDAQ:TARA) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 20, 2025 | marketbeat.comHC Wainwright Has Optimistic Outlook of TARA Q3 EarningsAugust 16, 2025 | marketbeat.comWe're Not Very Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn RateAugust 13, 2025 | finance.yahoo.comProtara Therapeutics Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comProtara Beats Q2 Loss EstimatesAugust 11, 2025 | aol.comAProtara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business UpdateAugust 11, 2025 | globenewswire.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | gurufocus.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | globenewswire.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - The Manila TimesJuly 2, 2025 | manilatimes.netMProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 2, 2025 | morningstar.comMProtara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial Community - NasdaqJuly 2, 2025 | nasdaq.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 1, 2025 | globenewswire.comProtara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial CommunityJune 30, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRNS, TARA, CGEN, and IKT Company DescriptionsCompugen NASDAQ:CGEN$1.36 -0.02 (-1.09%) As of 01:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Inhibikase Therapeutics NYSE:IKT$1.56 -0.04 (-2.25%) As of 01:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Marinus Pharmaceuticals NASDAQ:MRNSMarinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.Protara Therapeutics NASDAQ:TARA$3.12 -0.04 (-1.27%) As of 01:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Reddit Hits Record Highs: Why Wall Street Is Taking Notice Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
